Monoclonal antibodies in multiple sclerosis treatment: current and future steps.
作者信息
Helliwell Claire L, Coles Alasdair J
机构信息
Department of Clinical Neurosciences, Addenbrooke's Hospital, Cambridge, UK
出版信息
Ther Adv Neurol Disord. 2009 Jul;2(4):195-203. doi: 10.1177/1756285609337827.
Abstract
摘要
相似文献
1
Monoclonal antibodies in multiple sclerosis treatment: current and future steps.多发性硬化症治疗中的单克隆抗体：现状与未来进展
Ther Adv Neurol Disord. 2009 Jul;2(4):195-203. doi: 10.1177/1756285609337827.
2
Monoclonal Antibodies for Multiple Sclerosis Treatment.用于治疗多发性硬化症的单克隆抗体
Acta Med Port. 2015 Sep-Oct;28(5):640-51. doi: 10.20344/amp.6486. Epub 2015 Oct 30.
3
Extended dosing of monoclonal antibodies in multiple sclerosis.多发性硬化症中单克隆抗体的延长给药。
Mult Scler. 2022 Nov;28(13):2001-2009. doi: 10.1177/13524585211065711. Epub 2021 Dec 24.
4
Monoclonal antibodies - a revolutionary therapy in multiple sclerosis.单克隆抗体——多发性硬化症的革命性疗法。
Neurol Neurochir Pol. 2020;54(1):21-27. doi: 10.5603/PJNNS.a2020.0008. Epub 2020 Jan 24.
5
[Development of new therapies for multiple sclerosis].[多发性硬化症新疗法的研发]
Tidsskr Nor Laegeforen. 2011 May 6;131(8):832-6. doi: 10.4045/tidsskr.10.0077.
6
Monoclonal Antibodies in the Treatment of Relapsing Multiple Sclerosis: an Overview with Emphasis on Pregnancy, Vaccination, and Risk Management.单克隆抗体在复发性多发性硬化症治疗中的应用：重点关注妊娠、疫苗接种和风险管理的概述。
Neurotherapeutics. 2022 Apr;19(3):753-773. doi: 10.1007/s13311-022-01224-9. Epub 2022 Apr 4.
7
Parenteral Treatment of Multiple Sclerosis: The Advent of Monoclonal Antibodies.多发性硬化症的肠外治疗：单克隆抗体的出现。
Semin Neurol. 2016 Apr;36(2):140-7. doi: 10.1055/s-0036-1579695. Epub 2016 Apr 26.
8
A systematic review of the safety and efficacy of monoclonal antibodies for progressive multiple sclerosis.一项关于用于进展性多发性硬化症的单克隆抗体的安全性和疗效的系统评价。
Int Immunopharmacol. 2023 Jul;120:110266. doi: 10.1016/j.intimp.2023.110266. Epub 2023 May 18.
9
Monoclonal antibodies in the treatment of multiple sclerosis.单克隆抗体在多发性硬化症治疗中的应用。
Curr Med Chem. 2009;16(36):4858-68. doi: 10.2174/092986709789909585.
10
A Milestone in Multiple Sclerosis Therapy: Monoclonal Antibodies Against CD20-Yet Progress Continues.多发性硬化症治疗的里程碑：针对 CD20 的单克隆抗体——但进展仍在继续。
Neurotherapeutics. 2021 Jul;18(3):1602-1622. doi: 10.1007/s13311-021-01048-z. Epub 2021 Apr 20.
引用本文的文献
1
Efficacy of Vafidemstat in Experimental Autoimmune Encephalomyelitis Highlights the KDM1A/RCOR1/HDAC Epigenetic Axis in Multiple Sclerosis.瓦非司他在实验性自身免疫性脑脊髓炎中的疗效突显了多发性硬化症中的KDM1A/RCOR1/HDAC表观遗传轴。
Pharmaceutics. 2022 Jul 6;14(7):1420. doi: 10.3390/pharmaceutics14071420.
2
Anti-CD20 treatment effectively attenuates cortical pathology in a rat model of widespread cortical demyelination.抗 CD20 治疗可有效减轻广泛皮质脱髓鞘大鼠模型的皮质病理学改变。
J Neuroinflammation. 2021 Jun 15;18(1):138. doi: 10.1186/s12974-021-02189-w.
3
Current Immunological and Clinical Perspective on Vaccinations in Multiple Sclerosis Patients: Are They Safe after All?当前多发性硬化症患者疫苗接种的免疫和临床观点：它们终究安全吗？
Int J Mol Sci. 2021 Apr 8;22(8):3859. doi: 10.3390/ijms22083859.
4
Characterization of blood-brain barrier integrity in a B-cell-dependent mouse model of multiple sclerosis.在多发性硬化症的B细胞依赖性小鼠模型中血脑屏障完整性的特征分析
Histochem Cell Biol. 2019 Jun;151(6):489-499. doi: 10.1007/s00418-019-01768-6. Epub 2019 Jan 21.
5
Clinical pharmacology of alemtuzumab, an anti-CD52 immunomodulator, in multiple sclerosis.阿仑单抗的临床药理学：一种抗 CD52 免疫调节剂在多发性硬化症中的应用。
Clin Exp Immunol. 2018 Dec;194(3):295-314. doi: 10.1111/cei.13208. Epub 2018 Oct 1.
6
Disease-Modifying Treatment in Progressive Multiple Sclerosis.进展性多发性硬化症的疾病修正治疗
Curr Treat Options Neurol. 2018 Apr 7;20(5):12. doi: 10.1007/s11940-018-0496-3.
7
Effects of antibody disulfide bond reduction on purification process performance and final drug substance stability.抗体二硫键还原对纯化工艺性能及最终药物稳定性的影响。
Biotechnol Bioeng. 2017 Jun;114(6):1264-1274. doi: 10.1002/bit.26265. Epub 2017 Mar 6.
8
A mushroom extract Piwep from Phellinus igniarius ameliorates experimental autoimmune encephalomyelitis by inhibiting immune cell infiltration in the spinal cord.云芝提取物云芝菇（Piwep）通过抑制脊髓免疫细胞浸润改善实验性自身免疫性脑脊髓炎。
Biomed Res Int. 2014;2014:218274. doi: 10.1155/2014/218274. Epub 2014 Jan 27.
本文引用的文献
1
CD40-CD40L cross-talk integrates strong antigenic signals and microbial stimuli to induce development of IL-17-producing CD4+ T cells.CD40与CD40配体的相互作用整合了强烈的抗原信号和微生物刺激，以诱导产生白细胞介素-17的CD4+T细胞的发育。
Proc Natl Acad Sci U S A. 2009 Jan 20;106(3):876-81. doi: 10.1073/pnas.0810769106. Epub 2009 Jan 9.
2
New cases of progressive multifocal leukoencephalopathy after treatment with natalizumab.那他珠单抗治疗后发生的进行性多灶性白质脑病新病例。
Lancet Neurol. 2009 Jan;8(1):28-31. doi: 10.1016/S1474-4422(08)70281-3.
3
Alemtuzumab vs. interferon beta-1a in early multiple sclerosis.阿仑单抗与干扰素β-1a治疗早期多发性硬化症的对比
N Engl J Med. 2008 Oct 23;359(17):1786-801. doi: 10.1056/NEJMoa0802670.
4
Repeated subcutaneous injections of IL12/23 p40 neutralising antibody, ustekinumab, in patients with relapsing-remitting multiple sclerosis: a phase II, double-blind, placebo-controlled, randomised, dose-ranging study.复发缓解型多发性硬化症患者皮下重复注射IL12/23 p40中和抗体优特克单抗：一项II期、双盲、安慰剂对照、随机、剂量范围研究。
Lancet Neurol. 2008 Sep;7(9):796-804. doi: 10.1016/S1474-4422(08)70173-X.
5
Host T cells are the main producers of IL-17 within the central nervous system during initiation of experimental autoimmune encephalomyelitis induced by adoptive transfer of Th1 cell lines.在通过Th1细胞系的过继转移诱导实验性自身免疫性脑脊髓炎起始阶段，宿主T细胞是中枢神经系统内白细胞介素-17的主要产生者。
J Immunol. 2008 Jun 15;180(12):8066-72. doi: 10.4049/jimmunol.180.12.8066.
6
Rituximab in relapsing-remitting multiple sclerosis: a 72-week, open-label, phase I trial.利妥昔单抗治疗复发缓解型多发性硬化症：一项为期72周的开放标签I期试验。
Ann Neurol. 2008 Mar;63(3):395-400. doi: 10.1002/ana.21363.
7
B-cell depletion with rituximab in relapsing-remitting multiple sclerosis.利妥昔单抗治疗复发缓解型多发性硬化症中的B细胞清除
N Engl J Med. 2008 Feb 14;358(7):676-88. doi: 10.1056/NEJMoa0706383.
8
Daclizumab phase II trial in relapsing and remitting multiple sclerosis: MRI and clinical results.达利珠单抗治疗复发缓解型多发性硬化症的II期试验：MRI及临床结果
Neurology. 2007 Aug 21;69(8):785-9. doi: 10.1212/01.wnl.0000267662.41734.1f.
9
Regulatory CD56(bright) natural killer cells mediate immunomodulatory effects of IL-2Ralpha-targeted therapy (daclizumab) in multiple sclerosis.调节性CD56（明亮型）自然杀伤细胞介导白细胞介素-2受体α靶向治疗（达利珠单抗）在多发性硬化症中的免疫调节作用。
Proc Natl Acad Sci U S A. 2006 Apr 11;103(15):5941-6. doi: 10.1073/pnas.0601335103. Epub 2006 Apr 3.
10
Natalizumab plus interferon beta-1a for relapsing multiple sclerosis.那他珠单抗联合干扰素β-1a治疗复发型多发性硬化症。
N Engl J Med. 2006 Mar 2;354(9):911-23. doi: 10.1056/NEJMoa044396.
Zotero 插件